

Ryan M Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11548350/publications.pdf>

Version: 2024-02-01

32
papers

9,496
citations

279798

23
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

10175
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.	27.0	1,443
2	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010, 463, 88-92.	27.8	1,402
3	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011, 470, 115-119.	27.8	1,292
4	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015, 21, 922-926.	30.7	927
5	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	27.8	759
6	A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. <i>Cancer Cell</i> , 2020, 37, 551-568.e14.	16.8	589
7	Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2012, 21, 723-737.	16.8	460
8	Pathogenesis of Human B Cell Lymphomas. <i>Annual Review of Immunology</i> , 2012, 30, 565-610.	21.8	371
9	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 2349-2354.	7.1	355
10	Targeting pathological B cell receptor signalling in lymphoid malignancies. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 229-243.	46.4	342
11	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	27.8	276
12	B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma. <i>Seminars in Hematology</i> , 2015, 52, 77-85.	3.4	176
13	A Lipid Raft Environment Enhances Lyn Kinase Activity by Protecting the Active Site Tyrosine from Dephosphorylation. <i>Journal of Biological Chemistry</i> , 2003, 278, 20746-20752.	3.4	151
14	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13447-13454.	7.1	143
15	Lipid segregation and IgE receptor signaling: A decade of progress. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2005, 1746, 252-259.	4.1	129
16	Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. <i>Blood</i> , 2009, 113, 2508-2516.	1.4	113
17	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2016, 29, 494-507.	16.8	93
18	Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. <i>Immunological Reviews</i> , 2019, 291, 190-213.	6.0	91

#	ARTICLE	IF	CITATIONS
19	The B Cell Antigen Receptor and Overexpression of MYC Can Cooperate in the Genesis of B Cell Lymphomas. <i>PLoS Biology</i> , 2008, 6, e152.	5.6	79
20	Reconstitution of Regulated Phosphorylation of Fc̳RI by a Lipid Raft-excluded Protein-tyrosine Phosphatase. <i>Journal of Biological Chemistry</i> , 2005, 280, 1230-1235.	3.4	59
21	TLR Signaling Is Activated in Lymph Nodeâ€ Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. <i>Cancer Research</i> , 2019, 79, 360-371.	0.9	47
22	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 630-647.	5.0	30
23	Ibrutinib Treatment of CLL: The Cancer Fights Back. <i>Cancer Cell</i> , 2014, 26, 11-13.	16.8	28
24	Regulation of B cell receptor-dependent NF-̳B signaling by the tumor suppressor KLHL14. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6092-6102.	7.1	28
25	A New â€Brewâ€ of MALT1 Inhibitors. <i>Cancer Cell</i> , 2012, 22, 706-707.	16.8	22
26	MHC class II structural requirements for the association with Ig̳1̳2, and signaling of calcium mobilization and cell death. <i>Immunology Letters</i> , 2008, 116, 184-194.	2.5	20
27	HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. <i>Blood</i> , 2017, 129, 598-608.	1.4	20
28	Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy. <i>Annual Review of Cancer Biology</i> , 2019, 3, 429-455.	4.5	18
29	TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas. <i>Blood</i> , 2009, 114, 5016-5023.	1.4	17
30	B-cell receptor signaling in the genesis and maintenance of B-cell lymphoma. <i>Future Oncology</i> , 2008, 4, 591-594.	2.4	6
31	Pathogenic signaling in multiple myeloma. <i>Seminars in Oncology</i> , 2022, 49, 27-40.	2.2	6
32	Proximity Ligation Assay. <i>Methods in Molecular Biology</i> , 2019, 1956, 363-370.	0.9	4